Science & Technology
Science and Technology
Science and Technology
Thu, September 10, 2009
Wed, September 9, 2009 Skystar Bio-Pharmaceutical Company: Skystar Wins Local Government Bids to Expand Product Distribution
XI'AN, CHINA--(Marketwire - September 9, 2009) - Skystar Bio-Pharmaceutical Company (
"Our Praziquantel tablets position us to capture additional market share as local governments continue to move toward the most cost effective solutions rather than utilizing State-Owned Enterprise (SOE) products," said Mr. Weibing Lu, Skystar's Chairman and CEO. "These new contracts demonstrate Skystar's industry leadership position and signify important inroads into gaining additional local government bids in other Schistosomiasis endemic regions. Praziquantel and our other products offer significant advantages compared with SOE offerings, and we plan to continue to expand Skystar's product reach to local farmers through similar contractual agreements."
Schistosomiasis is a debilitating parasitic infection commonly known as "snail fever" or "blood fluke," and among the diseases that the Chinese government has focused on for identifying viable treatments and prevention. Controlling Schistosomiasis is a top priority of the Chinese government and a consistent public health concern as the widespread disease is easily contracted by both animals and humans from contact with contaminated water.
Praziquantel is a compound of pyrazine and isoquinolin designed to treat and prevent Schistosomiasis in livestock. Praziquantel tablets are absorbed by the host and kill both the grub and the adult parasites almost immediately. Praziquantel has shown significant advantages when compared with other currently marketed products, including fewer side effects and a considerably shortened treatment period. Currently marketed treatments take 10-to-20 days, while Praziquantel's treatment period is one-to-two days. Additionally, Skystar's Praziquantel tablets are more efficient requiring one-tenth the dosage of other currently marketed products.
About Skystar Bio-Pharmaceutical Company
Skystar is a China-based developer and distributor of veterinary healthcare and medical care products. Skystar has four product lines (veterinary medicines, micro-organisms, vaccines and feed additives) and over 170 products, with over 40 additional products in the developmental stage. Skystar has formed strategic sales distribution networks covering 29 provinces throughout China. For additional information, please visit [ http://www.skystarbio-pharmaceutical.com ].
To be added to the Company's email distribution for future news releases, please send your request to [ skystar@tpg-ir.com ].
Forward-looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the progress of new product development. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.
